期刊
CANCERS
卷 14, 期 15, 页码 -出版社
MDPI
DOI: 10.3390/cancers14153595
关键词
osmotic pump; chemoresistance; drug repurposing; EMT
类别
资金
- Natural Sciences and Engineering Research Council of Canada (NSERC) [388697]
- NSERC Alliance
- Josefowitz Family
- ENCYT Technologies Inc.
- Terry Fox Research Institute Transdisciplinary Training Program Cancers in Cancer Research (2017)
- 2019 Franklin Bracken Fellowship
- 2020 Queen Elizabeth II Graduate Scholarship in Science and Technology
- Mitacs Postdoctoral Fellowship
- 2021 R.S. McLaughlin Fellowship
- Queen's Graduate Award
Repositioning aspirin and oseltamivir phosphate in combination with gemcitabine treatment has shown promise as an effective treatment option for pancreatic cancer. The therapy disrupts chemoresistance, tumor progression, EMT program, cancer stem cells, and metastases in a preclinical mouse model. Additional investigation is warranted to evaluate its potential in clinical settings and improve patient prognosis for this otherwise fatal disease.
Simple Summary Repositioning old drugs in combination with clinical standard chemotherapeutics opens a promising clinical treatment approach for patients with pancreatic cancer. This report presents a therapeutic repositioning of continuous perfusion of aspirin and oseltamivir phosphate in combination with gemcitabine treatment as an effective treatment option for pancreatic cancer. The data suggest that repositioning these drugs with continuous perfusion with gemcitabine disables chemoresistance, tumor progression, EMT program, cancer stem cells, and metastases in a preclinical mouse model of human pancreatic cancer. These promising results warrant additional investigation to assess the potential of translating into the clinical setting to improve the cancer patient prognosis for an otherwise fatal disease. Metastatic pancreatic cancer has an invariably fatal outcome, with an estimated median progression-free survival of approximately six months employing our best combination chemotherapeutic regimens. Once drug resistance develops, manifested by increased primary tumor size and new and growing metastases, patients often die rapidly from their disease. Emerging evidence indicates that chemotherapy may contribute to the development of drug resistance through the upregulation of epithelial-mesenchymal transition (EMT) pathways and subsequent cancer stem cell (CSC) enrichment. Neuraminidase-1 (Neu-1) regulates the activation of several receptor tyrosine kinases implicated in EMT induction, angiogenesis, and cellular proliferation. Here, continuous therapeutic targeting of Neu-1 using parenteral perfusion of oseltamivir phosphate (OP) and aspirin (ASA) with gemcitabine (GEM) treatment significantly disrupts tumor progression, critical compensatory signaling mechanisms, EMT program, CSC, and metastases in a preclinical mouse model of human pancreatic cancer. ASA- and OP-treated xenotumors significantly inhibited the metastatic potential when transferred into animals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据